AI data becomes sticking point in biopharma dealmaking

As drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top